Induction of humoral immune responses and inhibition of metastasis in mice by a VEGF peptide-based vaccine.
Angiogenesis
Immunoinformatics
Metastasis
Peptide-based vaccine
VEGF
Journal
Iranian journal of basic medical sciences
ISSN: 2008-3866
Titre abrégé: Iran J Basic Med Sci
Pays: Iran
ID NLM: 101517966
Informations de publication
Date de publication:
Apr 2020
Apr 2020
Historique:
entrez:
4
6
2020
pubmed:
4
6
2020
medline:
4
6
2020
Statut:
ppublish
Résumé
Blocking of vascular endothelial growth factor (VEGF) plays a pivotal role in inhibition of metastasis and is a target for development of anti-angiogenic agents. In this study, a peptide-based vaccine was designed and its potential for induction of humoral immune responses, generation of neutralizing antibodies, inhibition of tumor growth and metastasis was determined. With online bioinformatics tools, a fragment of the VEGF-A was selected for a peptide-based vaccine. To enhance its antigenicity, the peptide was conjugated with The bioinformatics analysis of the selected region confirmed dis-similarity of the peptide with any other human protein and its acceptable antigenicity to stimulate a tumor-specific humoral response. Anti-VEGF antibody titers were significantly greater in vaccinated mice than in controls. IgG antibody from mice immunized with recombinant VEGF-A inhibited HUVEC proliferation ( Production of high-titer antibody against the peptide vaccine indicated that the peptide has the potency to be used as a peptide-based vaccine for humoral inhibition of tumor growth and metastasis. The efficacy of the peptide should be further tested in primate models.
Identifiants
pubmed: 32489566
doi: 10.22038/ijbms.2020.38508.9141
pmc: PMC7239427
doi:
Types de publication
Journal Article
Langues
eng
Pagination
507-514Références
Hybridoma (Larchmt). 2011 Apr;30(2):145-51
pubmed: 21529287
Nat Rev Cancer. 2008 Aug;8(8):579-91
pubmed: 18596824
Microcirculation. 2009 Oct;16(7):572-92
pubmed: 19521900
Vaccine. 2014 Apr 17;32(19):2241-50
pubmed: 24530151
Angiogenesis. 2017 May;20(2):185-204
pubmed: 28361267
Nature. 2011 May 19;473(7347):298-307
pubmed: 21593862
Int J Mol Sci. 2017 Aug 17;18(8):
pubmed: 28817103
J Transl Med. 2013 Apr 11;11:97
pubmed: 23578144
Cancer Immunol Immunother. 2007 Aug;56(8):1299-309
pubmed: 17502972
Vaccine. 2012 Jan 5;30(2):368-77
pubmed: 22075086
Mol Aspects Med. 2011 Apr;32(2):88-111
pubmed: 21565214
Proc Natl Acad Sci U S A. 2001 Sep 25;98(20):11545-50
pubmed: 11553767
Acta Med Okayama. 2011 Dec;65(6):353-62
pubmed: 22189475
Electrophoresis. 1995 Jun;16(6):948-51
pubmed: 7498141
Vaccine. 2010 Apr 26;28(19):3453-61
pubmed: 20197134
Proc Natl Acad Sci U S A. 2007 Feb 20;104(8):2837-42
pubmed: 17301234
Cancer Res. 1998 Apr 1;58(7):1486-93
pubmed: 9537252
Curr Clin Pharmacol. 2011 Aug;6(3):189-98
pubmed: 21827388
N Engl J Med. 2004 Jun 3;350(23):2335-42
pubmed: 15175435
Cancer Lett. 2013 Sep 28;338(2):219-28
pubmed: 23707856
Gynecol Oncol. 2010 Dec;119(3):564-70
pubmed: 20822802
Oncoimmunology. 2012 Dec 1;1(9):1557-1576
pubmed: 23264902
Angiogenesis. 2008;11(4):381-93
pubmed: 19034678
Exp Eye Res. 2014 May;122:102-9
pubmed: 24675387
Eur J Surg Oncol. 2006 May;32(4):363-70
pubmed: 16520018
Clin Exp Metastasis. 1999 Mar;17(2):163-70
pubmed: 10411109
J Immunol Methods. 1990 Jul 3;130(2):195-200
pubmed: 2115551
Expert Opin Emerg Drugs. 2008 Jun;13(2):295-308
pubmed: 18537522
Cancer Treat Res. 2005;123:115-36
pubmed: 16211868
Sci Rep. 2013 Nov 29;3:3380
pubmed: 24287585
J Biol Chem. 2011 Apr 15;286(15):13612-25
pubmed: 21321115
BMC Res Notes. 2018 Jan 12;11(1):21
pubmed: 29329598
Nat Rev Clin Oncol. 2009 Jul;6(7):395-404
pubmed: 19424102
N Engl J Med. 1971 Nov 18;285(21):1182-6
pubmed: 4938153
J Immunol Methods. 1985 Apr 8;78(1):59-69
pubmed: 2580027